TALPHERA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.042 USD | +5.21% |
|
+6.07% | +36.50% |
| 03-06 | Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-06 | Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024 |
| Sales 2024 * | 682K 54.47M | Sales 2025 * | 2.5M 200M | Capitalization | 16.8M 1.34B |
|---|---|---|---|---|---|
| Net income 2024 * | -20M -1.6B | Net income 2025 * | -21M -1.68B | EV / Sales 2024 * | 24.6 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.71 x |
| P/E ratio 2024 * |
-1.04
x | P/E ratio 2025 * |
-1.05
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Talphera, Inc.
More recommendations
More press releases
| 1 day | +1.34% | ||
| 1 week | +6.07% | ||
| Current month | -2.59% | ||
| 1 month | -6.23% | ||
| 3 months | -2.59% | ||
| 6 months | +96.73% | ||
| Current year | +36.50% |
1 week
0.95
1.14
1 month
0.921.24
Current year
0.721.61
1 year
0.431.61
3 years
0.4333.40
5 years
0.4377.92
10 years
0.43233.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pamela Palmer
FOU | Founder | 61 | 12/07/05 |
Vincent Angotti
CEO | Chief Executive Officer | 56 | 05/03/17 |
Raffi Asadorian
DFI | Director of Finance/CFO | 54 | 31/07/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Wan
BRD | Director/Board Member | 58 | 31/07/06 |
Adrian Adams
CHM | Chairman | 73 | 10/02/13 |
| Director/Board Member | 70 | 31/01/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 1.042 | +5.21% | 6 064 |
| 29/04/24 | 0.99 | -5.71% | 41,489 |
| 26/04/24 | 1.05 | -6.25% | 39,947 |
| 25/04/24 | 1.12 | +15.46% | 259,785 |
| 24/04/24 | 0.97 | +2.55% | 32,552 |
Delayed Quote Nasdaq, April 30, 2024 at 02:46 pm
More quotes
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.99
USD
Average target price
5.125
USD
Spread / Average Target
+417.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.50% | 16.8M | |
| +3.16% | 69.85B | |
| +11.77% | 8.98B | |
| -14.44% | 4.89B | |
| +41.60% | 4.44B | |
| +5.96% | 3.95B | |
| +22.87% | 2.49B | |
| -19.32% | 2.4B | |
| -27.04% | 2.28B | |
| +7.97% | 1.96B |
- Stock Market
- Equities
- TLPH Stock
